.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 5,922,304

« Back to Dashboard

Details for Patent: 5,922,304

Title: Gaseous precursor filled microspheres as magnetic resonance imaging contrast agents
Abstract:Novel gas filled microspheres useful as magnetic resonance imaging (MRI) contrast agents are provided.
Inventor(s): Unger; Evan C. (Tucson, AZ)
Assignee: Imarx Pharmaceutical Corp. (Tucson, AR)
Filing Date:Mar 09, 1995
Application Number:08/401,974
Claims:1. A method of providing an image of an internal region of a patient comprising (i) administering to the patient a gaseous precursor filled microsphere, wherein said microsphere contains substantially no sulfide linkages and consists essentially of one or more lipids, one or more lipids bearing polymers, or combinations thereof, (ii) allowing the gaseous precursor to undergo a phase transition from a liquid to a gas in the patient, and (iii) scanning the patient using magnetic resonance imaging to obtain visible images of said region.

2. A method for diagnosing the presence of a diseased tissue or region in a patient comprising (i) administering to the patient a gaseous precursor filled microsphere, wherein said microsphere contains substantially no sulfide linkages and consists essentially of one or more lipids, one or more lipids bearing polymers, or combinations thereof, (ii) allowing the gaseous precursor to undergo a phase transition from a liquid to a gas in the patient, and (iii) scanning the patient using magnetic resonance imaging to obtain visible images of any diseased tissue or region in the patient.

3. A method according to claim 1 or 2 wherein the region is the vasculature.

4. A method according to claim 1 or 2 wherein the region is the cardiovascular region.

5. A method according to claim 1 or 2 wherein the region is the gastrointestinal region.

6. A method according to claim 1 or 2 wherein the scanning is of the vasculature of the patient.

7. A method according to claim 1 or 2 wherein the scanning is of the cardiovascular region of the patient.

8. A method according to claim 1 or 2 wherein the scanning is of the gastrointestinal region of the patient.

9. A method according to claim 1 or 2 wherein the scanning is of a region of the patient selected from the following: intranasal tract; auditory canal; intraocular region; intraperitoneal region; kidneys; urethra; and genitourinary tract.

10. A method of claim 1 wherein said lipid is a phospholipid.

11. A method of claim 2 wherein said lipid is a phospholipid.

12. A method of claim 1 wherein said microsphere comprises a monolayer.

13. A method of claim 12 wherein said monolayer comprises a phospholipid.

14. A method of claim 2 wherein said microsphere comprises a monolayer.

15. A method of claim 14 wherein said monolayer comprises a phospholipid.

16. A method of claim 1 wherein said gaseous precursor is a perfluorocarbon.

17. A method of claim 11 wherein said gaseous precursor is selected from the group consisting of sulfur hexafluoride, perfluoromethane, perfluoroethane, perfluoropropane, perfluorocyclopropane, perfluorobutane, perfluorocyclobutane, perfluoropentane, perfluorocyclopentane, perfluorohexane, and perfluoroheptane.

18. A method of claim 17 wherein said gaseous precursor is perfluorohexane.

19. A method of claim 17 wherein said gaseous precursor is perfluoropropane.

20. A method of claim 17 wherein said gaseous precursor is selected from the group consisting of perfluoropentane, perfluorocyclopentane, perfluorohexane, and perfluoroheptane.

21. A method of claim 20 wherein said gaseous precursor is perfluoropentane.

22. A method of claim 1 wherein said microsphere is rehydrated from a lyophilized microsphere.

23. A method of claim 1 wherein said lipid microsphere comprises at least 70 mole percent of at least one lipid.

24. A method of claim 1 wherein said lipid microsphere comprises at least two lipids wherein said first lipid contains substantially no linkages to a polymer and comprises at least 70 mole percent of the total moles of the microsphere, and wherein said second lipid bears a hydrophilic polymer.

25. A method of claim 24 wherein said first lipid comprises: (i) a neutral lipid, and (ii) a negatively charged lipid, wherein the amount of said negatively charged lipid is greater than 1 mole percent of total lipids present.

26. A method of claim 25 wherein said negatively charged lipid is phosphatidic acid.

27. A method of claim 24 wherein the hydrophilic polymer of said second lipid is selected from the group consisting of polyethyleneglycol, polypropyleneglycol, polyvinylalcohol, and polyvinylpyrrolidone and copolymers thereof.

28. A method of claim 24 wherein the lipids comprise about 77.5 mole percent dipalmitoyl-phosphatidylcholine, about 12.5 mole percent of dipalmitoyl-phosphatidic-acid, and about 10 mole percent of dipalmitoylphosphatidylethanolamine-polyethyleneglycol 5000.

29. A method of claim 24 wherein the lipids comprise about 82 mole percent dipalmitoylphosphatidyl-choline, about 10 mole percent of dipalmitoylphosphatidic acid, and about 8 mole percent of dipalmitoylphosphatidyl-ethanolamine-polyethyleneglycol 5000.

30. A method of claim 2 wherein said gaseous precursor is a perfluorocarbon.

31. A method of claim 2 wherein said gaseous precursor is selected from the group consisting of sulfur hexafluoride, perfluoromethane, perfluoroethane, perfluoropropane, perfluorocyclopropane, perfluorobutane, perfluorocyclobutane, perfluoropentane, perfluorocyclopentane, perfluorohexane, and perfluoroheptane.

32. A method of claim 31 wherein said gaseous precursor is perfluorohexane.

33. A method of claim 31 wherein said gaseous precursor is perfluoropropane.

34. A method of claim 31 wherein said gaseous precursor is selected from the group consisting of perfluoropentane, perfluorocyclopentane, perfluorohexane, and perfluoroheptane.

35. A method of claim 31 wherein said gaseous precursor is perfluoropentane.

36. A method of claim 2 wherein said microsphere is rehydrated from a lyophilized microsphere.

37. A method of claim 2 wherein said lipid microsphere comprises at least 70 mole percent of at least one lipid.

38. A method of claim 2 wherein said lipid microsphere comprises at least two lipids wherein said first lipid contains substantially no linkages to a polymer and comprises at least 70 mole percent of the total moles of the microsphere, and wherein said second lipid bears a hydrophilic polymer.

39. A method of claim 38 wherein said first lipid comprises: (i) a neutral lipid, and (ii) a negatively charged lipid, wherein the amount of said negatively charged lipid is greater than 1 mole percent of total lipids present.

40. A method of claim 39 wherein said negatively charged lipid is phosphatidic acid.

41. A method of claim 38 wherein the hydrophilic polymer of said second lipid is selected from the group consisting of polyethyleneglycol, polypropyleneglycol, polyvinylalcohol, and polyvinylpyrrolidone and copolymers thereof.

42. A method of claim 38 wherein the lipids comprise about 77.5 mole percent dipalmitoyl-phosphatidylcholine, about 12.5 mole percent of dipalmitoyl-phosphatidic acid, and about 10 mole percent of dipalmitoylphosphatidylethanolamine-polyethyleneglycol 5000.

43. A method of claim 38 wherein the lipids comprise about 82 mole percent dipalmitoylphosphatidyl-choline, about 10 mole percent of dipalmitoylphosphatidic acid, and about 8 mole percent of dipalmitoylphosphatidyl-ethanolamine-polyethyleneglycol 5000.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc